ClinicalTrials.gg
RecruitingNCT07374705BIR 1Updated Feb 25, 2026

Disentangling the Effect of Brain Insulin Resistance on Brain Health

An observational study in Diabetes Type 2 and Diabetes Type 1, sponsored by Henrik Bo Wiberg Larsson. Recruiting at 3 sites in 2 countries. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Henrik Bo Wiberg Larsson · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
150
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark — 44 open to participants now, 62 under way, 8 of them phase 3. Diabetes Mellitus, Type 2 · Denmark.

Planned enrollment
49th of 97
150 · median 150
Started
2026
with 22 others
Observational
97 of 478
15 open now
Primary completion
2031-10
later than 61 of 61 live
Registered
457th of 478
by date

Among the 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark, this one is the 49th largest by planned enrollment of the 97 observational ones that give a count, is one of 23 that started in 2026, is one of 97 observational ones, reaches primary completion later than 61 of the 61 other live ones, and was the 457th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 478 studies in Diabetes Mellitus, Type 2 with a site in Denmark, or all of them as a file.
02

Study summary

People with diabetes are at increased risk of developing dementia, including Alzheimer's disease and vascular dementia. In addition, persons with diabetes have more pronounced age-related brain atrophy and cognitive difficulties compared to people without diabetes. The mechanisms behind the effects on the brain of diabetes are still unclear. New research suggests that the brains of some people with diabetes do not respond normally to insulin signals, a condition known as brain insulin resistance (BIR). To date, there have been no large clinical studies investigating BIR and its impact on brain health, but several smaller studies suggest that BIR may be a cause of cognitive decline and impaired brain health in people with diabetes. Another mechanism that may contribute to impaired brain health in people with diabetes is damage to the blood vessels in the brain. Damage to blood vessels is a well-known complication of diabetes, but how it affects the brain is not fully described. In this project, we will investigate the relationship between BIR and brain blood vessel dysfunction and its relationship to cognition and brain function. This is done by examining patients with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy controls. The participants will undergo MRI brain scans to assess the impact of BIR on the brain physiology and to evaluate brain blood vessel health. Participants will undergo comprehensive assessments of their cognitive abilities and thorough health examination.

Read the detailed description

The BIR-BrainHealth project investigates the role of brain insulin resistance (BIR) as a key mechanism linking diabetes to cognitive decline and dementia risk. By combining cognitive testing with advanced neuroimaging (MRI and PET), metabolic profiling, and multi-omics analyses, the study aims to uncover how BIR affects brain physiology, energy metabolism, and neurovascular function. The present trial registration specifically covers the MRI components of the project and does not include PET imaging.

Diabetes significantly increases the risk of mild cognitive impairment and dementia. The exact link between diabetes and cognitive decline is yet to be fully understood. Early cognitive decline in diabetes suggests a unique pathogenetic trajectory. One hypothesized mechanism involves impaired insulin signaling/transport in the brain, referred to as brain insulin resistance (BIR). Evidence indicates that in some individuals with diabetes, neuronal insulin signaling is abnormal, resulting in dysregulated cerebral metabolism and function. Another possible pathway is cerebrovascular pathology, which may compromise cerebral perfusion and energy metabolism. The present project will investigate the relationship between BIR and cerebrovascular dysfunction, and their impact on cognition and brain function.

We will set up a multicenter study in Denmark and Germany. Initially the study will include 50 participants with type 1 diabetes, 50 participants with type 2 diabetes, and 50 control participants without diabetes. All participants will undergo a comprehensive clinical evaluation to characterize diabetes duration, severity, and systemic comorbidities. The cognitive performance of the participants will be assessed using a neuropsychological test battery of following standardized tests:

  • Rey Auditory Verbal Learning Test (RAVLT)
  • Trail Making Test (TMT) part A and B
  • Symbol Digit Modalities Test (SDMT)
  • RBANS Digit Span forward (Version A)
  • Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS)
  • Verbal Fluency test (phonetic and semantic)
  • Grooved Pegboard
  • Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses
  • The Montreal Cognitive Assessment (MoCA)

Tests will be grouped by cognitive domains, and each domain score is calculated as the mean of the individual component z-scores. A cognitive composite (global score) will be derived from the mean of the domains: learning and memory, executive function and working memory, processing speed, and attention.

Magnetic resonance imaging (MRI) will be performed to assess BIR and structural brain changes, including atrophy. All MRI-scans will be performed on a research-optimized 3 Tesla MRI scanner. BIR will be evaluated by measuring changes in cerebral perfusion from administration of intranasal insulin delivered via nasal spray.

Blood, urine and stool will be collected for biomarker development and characterization of patients with BIR. A multi-omics approach will be applied to identify reliable biomarkers of BIR, incorporating lipidomics, metabolomics, proteomics, and transcriptomics. Lipidomic analysis will quantify approximately 650 lipid species, including phospholipids, lysophos-pholipids, ceramides, sphingolipids, diacylglycerols, and triacylglycerols, using liquid chromatography-mass spectrometry. Metabolomic profiling will measure approximately 300 metabolites, including citric acid cycle intermediates, short-chain fatty acids, ketones, and amino acids, using gas chromatography-mass spectrometry. Proteomic analysis will be conducted using a validated, clinically applicable mass spectrometry method, and transcriptomic profiling will be performed using RNA-based methods. The participants will be genotyped using the Illumina Infinium Global Screening Array (GSA v2.4), with exclusion of rare variants and clinically relevant mutations listed by the American College of Medical Genetics, in accordance with the guidelines of the National Science Ethics Committee on genomic research.

A subset of participants will undergo additional advanced MRI-scanning for assessments of cerebro-vascular function. Brain perfusion, blood-brain barrier integrity, and capillary perfusion distribution will be measured using dynamic contrast-enhanced MRI. Cerebrovascular reactivity will be measured by perfusion-weighted MRI during inhalation of air enriched with 5% CO2, a potent cerebral vasodilator. Cerebral blood flow responses to neuronal activation induced by visual stimulation will be assessed using perfusion-weighted MRI. Lastly, in a subset of participants the brain glucose sensing will be assessed using functional MRI (fMRI). fMRI will be measured prior to, during and following oral ingestion of water containing 75 grams of glucose. The glucose drink is given through a straw while the participants are lying in the scanner and will be consumed over a period of 5 minutes. Blood samples will be collected throughout the scan for measurements of blood glucose.

03

Conditions studied

  • Diabetes Type 2
  • Diabetes Type 1

Keywords

  • Diabetes
  • Brain Insulin Resistance
  • cognitive performance
  • cognitive dysfunction
  • structural changes in the brain
  • cerebrovascular function
  • brain health
  • blood-brain-barrier
  • diabetes type 1
  • diabetes type 2
  • biomarkers
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

It is planned to recruit participants in the Greater Copenhagen area in Denmark and the Ulm area in Germany. The participants will be recruited from the outpatient clinic at Steno Diabetes Center Copenhagen and Ulm University Hospital and primary care settings in Denmark and Germany.

In addition to this, participants will be sought by physical advertisements in the local area, through recruitment platforms (join.trialtree.com) and social media.

Eligibility criteria

Inclusion Criteria (all):

  • age 50-80 years

Inclusion Criteria (diabetes only):

  • Diagnosis of either type 1 diabetes or type 2 diabetes
  • Diabetes duration of ≥10 years for individuals with type 1 diabetes and ≥5 years for individuals with type 2 diabetes

Exclusion Criteria:

  • >100 mmol/mol
  • Other type of diabetes
  • Weight >140 Kg
  • Treatment with drugs that cannot be paused for 12 hours
  • Diagnosis of dementia
  • Active and recent (1year) malignant disease
  • History of major stroke
  • Major depression and/or treatment with antipsychotics
  • History of traumatic brain injury
  • Other medical condition or disorder (e.g., epilepsy, recent concussion) that in the opinion of the investigator precludes compliance with the protocol, evaluation of the results or represent an unacceptable risk for the participant's safety.
  • Inability to perform neuropsychological tests (e.g., severe vision and hearing impairment that cannot be improved with aids such as glasses and hearing aids, or language barrier.)
  • Severe claustrophobia
  • Foreign bodies of metal in the body which prohibits brain MRI scans (e.g. pacemaker or screws/plates from surgery in the head or neck region)
  • Participants who do not wish to be informed about accidental findings by MRI
  • measurement \<45 within 3 months of study visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Type 1 Diabetes

    Individuals who have a type 1 diabetes diagnose and meet the inclusion and exclusion criteria.

  • Type 2 Diabetes

    Individuals who have a type 2 diabetes diagnose and meet the inclusion and exclusion criteria.

  • Controls

    Individuals who do not have a diabetes diagnose and meet the inclusion and exclusion criteria.

06

What researchers measure

Primary outcomes

  1. Correlation between brain insulin response and cognitive measures

    Brain insulin response is assessed by measuring changes in cerebral blood flow following intranasal insulin administration, using arterial spin labelling (ASL) MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

  2. Correlation between cerebrovascular reactivity and cognitive measures

    Cerebrovascular reactivity is assessed by measuring changes in cerebral blood flow responses to inhalation of hypercapnic air (air enriched with 5% CO2). Cerebral blood flow is measured using combined blood-oxygen-level-dependent (BOLD) MRI, ASL MRI, and phase contrast mapping (PCM) MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

Secondary outcomes

  1. Blood-brain-barrier permability

    Differences in blood-brain-barrier permeability between groups, measured by dynamic contrast enhanced MRI.

    Time frame: Baseline (only measured once)

  2. Neurovascular coupling

    Differences in cerebral blood flow responses to visual stimulation between groups, assessed with ASL MRI.

    Time frame: Baseline (only measured once)

  3. Hypothalamic glucose sensing

    Differences in cerebral blood flow response in the hypothalamus to glucose ingestion between groups, assessed by combined BOLD and ASL MRI.

    Time frame: Baseline (only measured once)

Other outcomes

  1. Brain insulin response

    Differences in brain insulin response between groups, assessed by measuring changes in cerebral blood flow following intranasal insulin administration using ASL MRI.

    Time frame: Baseline (only measured once)

  2. Cerebrovascular reactivity

    Differences in cerebrovascular reactivity between groups, assessed by measuring changes in cerebral blood flow in response to inhalation of hypercapnic air (air enriched with 5% CO2). Cerebral blood flow is measured using combined blood-oxygen-level-dependent (BOLD) MRI, ASL MRI, and phase contrast mapping (PCM) MRI.

    Time frame: Baseline (only measured once)

  3. Brain atrophy and white matter lesion

    Differences in brain atrophy and white matter lesion load between groups, assessed by T1- weighted structural MRI and Fluid-Attenuated Inversion Recovery (FLAIR) MRI.

    Time frame: Baseline (only measured once)

  4. Correlation between brain atrophy and white matter lesions load and cognitive measures

    Brain atrophy and white matter lesion load is assessed by T1- weighted structural MRI and FLAIR MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

  5. Cerebral microbleeds

    Differences in the amount of cerebral microbleeds between groups, assessed by susceptibility-weighted MRI.

    Time frame: Baseline (only measured once)

  6. Correlation between cerebral microbleeds and cognitive measures

    Cerebral microbleeds is assessed by susceptibility-weighted MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

  7. Structural connectivity

    Differences in structural connectivity between groups, assessed by diffusion tensor imaging (DTI) MRI.

    Time frame: Baseline (only measured once)

  8. Correlation between structural connectivity and cognitive measures

    Structural connectivity is assessed by DTI MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

  9. White matter diffusion integrity

    Differences in white matter diffusion parameters between groups, assessed by DTI MRI.

    Time frame: Baseline (only measured once)

  10. Correlation between white matter diffusion integrity and cognitive measures

    White matter diffusion is assessed by DTI MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once

  11. Cerebral blood flow

    Differences in resting cerebral blood flow between groups, assessed by ASL and PCM MRI.

    Time frame: Baseline (only measured once)

  12. Correlation between resting cerebral blood flow and cognitive measures

    Resting cerebral blood flow is assessed by ASL and PCM MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

  13. Cerebral metabolic rate of oxygen

    Differences in resting cerebral metabolic rate of oxygen between groups, assessed by combined PCM MRI and susceptibility-based oximetry (SBO) MRI.

    Time frame: Baseline (only measured once)

  14. Correlation between cerebral metabolic rate of oxygen and cognitive measures

    Cerebral metabolic rate of oxygen is assessed by combined PCM MRI and SBO MRI. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

  15. Regional brain glucose sensing

    Differences in regional cerebral blood flow in response to glucose ingestion between groups, assessed by combined BOLD and ASL MRI.

    Time frame: Baseline (only measured once)

  16. Correlation between hypothalamic glucose sensing and biomarkers

    Cerebral blood flow response in the hypothalamus to glucose ingestion is assessed by combined BOLD and ASL MRI. A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify reliable biomarkers of brain insulin sensing.

    Time frame: Baseline (only measured once)

  17. Correlation between brain insulin response and hypothalamic glucose sensing

    Brain insulin response is assessed by measuring changes in cerebral blood flow following administration of intranasal insulin using arterial spin labelling ASL MRI. Cerebral blood flow response in the hypothalamus to glucose ingestion is measured by combined BOLD and ASL MRI.

    Time frame: Baseline (only measured once)

  18. Biomarkers of neuronal damage, neuroinflammation, and brain insulin response

    Brain insulin response is assessed by measuring changes in cerebral blood flow following administration of intranasal insulin using ASL MRI. A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify biomarkers of neuronal damage, neuroinflammation and brain insulin resistance.

    Time frame: Baseline (only measured once)

  19. Biomarkers of blood-brain-barrier integrity and cerebrovascular function

    Blood-brain-barrier permeability is assessed by dynamic contrast enhanced MRI A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify biomarkers of vascular function and blood brain barrier integrity.

    Time frame: Baseline (only measured once)

  20. Correlation between biomarkers and cognitive measures

    A multiomics approach integrating lipidomics, metabolomics, proteomics, transcriptomics, and genotyping will be used to identify biomarkers of cognition. The neuropsychological test battery includes the following: * Rey Auditory Verbal Learning Test (RAVLT) * Trail Making Test (TMT) part A and B * Symbol Digit Modalities Test (SDMT) * RBANS Digit Span forward (Version A) * Wechsler Adult Intelligence Scale III Letter-Number Sequencing test (WAIS-LNS) * Verbal Fluency test (phonetic and semantic) * Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) using A' (RVP-A) and mean latency for correct responses Motor function (Grooved Pegboard) Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline (only measured once)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Wangler S, Sorensen P, Kass K, Jensen NJ, Vestergaard MB, Hummel J, Volk R, Antvorskov JC, Pociot F, Rungby J, Heni M, Larsson HBW. Disentangling the effect of brain insulin resistance on brain health (BIR-BrainHealth): Rationale and study protocol. Diabet Med. 2026 Jul 2:e70415. doi: 10.1111/dme.70415. Online ahead of print. PubMed 42394131 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Oct 2031, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 29, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Oct 2031
CompletionEst.
Jan 2032
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07374705
Lead sponsor
Henrik Bo Wiberg Larsson
Responsible party
Henrik Bo Wiberg Larsson (Professor, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Jan 29, 2026
Start date
Jan 1, 2026
Primary completion
Oct 2031 (estimated)
Completion
Jan 2032 (estimated)
Last update
Feb 25, 2026

Study contacts

Henrik BW Larsson, Professor
Contact
henrik.bo.wiberg.larsson@regionh.dk
+45 24824294
Henrik BW Larsson, Professor
principal investigator · Rigshospitalet, Denmark
Jørgen Rungby, Professor
principal investigator · Steno Diabetes Center Copenhagen
Flemming Pociot, Professor
principal investigator · Steno Diabetes Center Copenhagen
Martin Heni, Professor
principal investigator · University of Ulm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion